TNYA Tenaya Therapeutics, Inc. Insider Trading

10% owner sells all 4,170,266 shares of TNYA for $2.4M (blended $0.57) as stock down 71% from 52-week high, unprofitable company.

COLUMN GROUP III GP, LP, a 10% owner, executed 4 separate sales on 2026-02-24 and 2026-02-25, selling 4,170,266 shares totaling $2,380,189.07 at prices ranging from $0.56 to $0.62, liquidating its entire position. The transaction occurs as Tenaya Therapeutics stock trades 71.0% below its 52-week high of $2.10 and has declined 56.4% over the prior 90 days, while the company reported net income of $-20,275,000.00 ($-20.3M) over its most recent full fiscal year. The complete divestiture by a major shareholder coincides with significant share price deterioration and ongoing unprofitability, which constitutes a notable capital event for investors monitoring shareholder conviction and cash position changes at this early-stage therapeutics company.

10% owner COLUMN GROUP III GP, LP sells 4.40M shares (62.4% of holdings) for $3.0M at $0.69–$0.82

COLUMN GROUP III GP, LP, a 10% owner of Tenaya Therapeutics, executed 4 separate sales on 2026-02-10 and 2026-02-11, liquidating 4,400,290 shares for $3,042,222.34 at prices ranging from $0.68 to $0.82. This represents a reduction of 62.4% of the insider's pre-transaction holdings (from 7,052,107 shares to 2,651,817 shares), constituting a material reduction of a significant stake. The timing of the sales coincides with Tenaya trading at $0.68 current price, down 67.6% from its 52-week high of $2.10 and down 48.9% over 90 days, while the company reported negative net income of $-20,275,000.00 for its most recent full fiscal year. The insider's cross-ticker track record shows 20 prior purchases with an average 90-day return of +35.6%, suggesting a pattern of open-market acquisitiveness historically; this large, multi-day liquidation of a major block stands in contrast to that historical buy orientation and warrants examination of whether capital or strategic pressures drove the exit.

Director David Goeddel bought 35,714,284 shares of TNYA at $0.70 ($25.0M) on 2025-03-05, tripling his stake to 49,313,559 shares amid -93.2% 52-week decline.

David Goeddel, a Director, deployed $24,999,998.80 to purchase 35,714,284 shares at $0.70, increasing his holdings by 262.6% to 49,313,559 shares. The company is currently trading at $0.46—93.2% below its 52-week high of $6.80—and has declined 87.2% over 90 days. The underlying business shows negative fundamentals: net income of $-25,634,000 over the most recent full fiscal year and a market cap of $36,441,437.36, indicating a loss-making enterprise with limited market valuation. While Goeddel's cross-ticker track record shows an 80% 90-day win rate with average 90-day returns of +96.6%, his prior buy at TNYA on 2024-02-12 delivered a -6.7% 90-day return, suggesting this insider's historical accuracy does not necessarily extend to this specific stock. The magnitude of capital deployed (approximately 69% of current market cap in a single transaction) and the timing during a steep drawdown merit investor scrutiny of the underlying business fundamentals and the rationale for this substantial increase in directional exposure.

10% owner COLUMN GROUP III GP, LP purchases 35,714,284 shares at $0.70, boosting stake to 49.31M; stock now -93.2% from 52-week high.

COLUMN GROUP III GP, LP increased its stake in Tenaya Therapeutics by 262.6%, purchasing 35,714,284 shares for $24,999,998.80 on 2025-03-05 at $0.70 per share. The company currently trades at $0.46 (down 55.8% in 30 days and 87.2% in 90 days), representing a 93.2% decline from its 52-week high of $6.80. Across the insider's cross-ticker open-market history, prior buys averaged -16.9% 30-day return and -21.6% 90-day return with a 0% win rate; at this specific ticker, the insider's prior buy on 2024-02-12 saw a -6.7% 90-day return. Against this backdrop of persistent unfavorable timing patterns and a company posting net losses of $25,634,000 with a market capitalization of only $36,441,437.36, the decision to deploy $25M in additional capital requires investor scrutiny regarding the insider's conviction thesis and access to information not yet public.